Skip to main content
OpenTrials

Clinical trial condition

Urologic Neoplasms

Explore clinical trials studying Urologic Neoplasms. Study availability and eligibility vary by location and protocol.

2,952 public trials 631 recruiting studies
Refine in advanced search Browse all conditions

Urologic Neoplasms trial results

Active, Not Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371

Conditions
Adnexal Diseases, Advanced Solid Tumor Historically Known for High EphA2 Expression, Breast Diseases, +49 more
Locations
  • California Cancer Associates for Research and Excellence, Inc. Encinitas, California, United States
  • University of California - Irvine Medical Center Orange, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT04561362

Conditions
Adnexal Diseases, Advanced Solid Tumor, Breast Diseases, +30 more
Locations
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Ocala Oncology Center Ocala, Florida, United States
  • Advent Health Orlando, Florida, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View all 24 locations
View Trial Details
Active, Not Recruiting

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

NCT06132945

Conditions
Adenocarcinoma, Brain Diseases, Brain Metastases, +21 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital ( Site 6009) Chongqing, Chongqing Municipality, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036) Guangzhou, Guangdong, China
View all 17 locations
View Trial Details

Related conditions